The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models

BACKGROUND: Cetuximab is the only targeted agent approved for the treatment of head and neck squamous cell carcinomas (HNSCC), but low response rates and disease progression are frequently reported. As the phosphoinositide 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) pathways have an...

Descripción completa

Detalles Bibliográficos
Autores principales: D'Amato, V, Rosa, R, D'Amato, C, Formisano, L, Marciano, R, Nappi, L, Raimondo, L, Di Mauro, C, Servetto, A, Fusciello, C, Veneziani, B M, De Placido, S, Bianco, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4056056/
https://www.ncbi.nlm.nih.gov/pubmed/24823695
http://dx.doi.org/10.1038/bjc.2014.241

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4056056/
https://www.ncbi.nlm.nih.gov/pubmed/24823695
http://dx.doi.org/10.1038/bjc.2014.241

Ejemplares similares